Printer Friendly

Beckman Coulter and Bio-Rad Agree to New Access Immunoassay System Distribution Arrangement.

Business Editors/Health and Medical Writers


FULLERTON, Calif.--(BW HealthWire)--Sept. 11, 2000

Beckman Coulter, Inc (NYSE:BEC) announced today that it has agreed with Bio-Rad Laboratories, Inc. (Amex: BIO.A; BIO.B) not to renew a distribution contract for the Access(R) immunoassay system in 90 markets throughout Europe, Africa and the Pacific Rim. As a result, Beckman Coulter will assume sales responsibility for the instrument system and related test kits in these areas beginning September 2000.

The Access system is a random-access benchtop analyzer that performs a variety of assays, including test panels for cancer, anemia, cardiac, fertility, thyroid, infectious disease, blood virus, cancer, allergy and diabetes. In 1997, Beckman Coulter, then Beckman Instruments, Inc., purchased this product business from the Pasteur Sanofi Diagnostics (PSD) division of the French company, Sanofi. At that time, PSD became Beckman Coulter's distributor in geographic territories where their strength in blood virus and infectious disease assays was strategically important to both companies.

"Beckman Coulter's successful development in the immunoassay market and Bio-Rad's acquisition of Sanofi prompted both companies to review the strategic intent of our relationship," commented Beckman Coulter Chairman, President and Chief Executive Officer John P. Wareham. "In order for Beckman Coulter to leverage our strength in total laboratory workflow and to optimize the value it creates for our customers, our conversations with Bio-Rad have led to the conclusion that it is in the best interest of both companies not to renew this agreement."

"This is a positive step that will give both companies more flexibility and potential for growth," commented Bio-Rad President and CEO David Schwartz. "Bio-Rad can continue its focus on its core clinical diagnostic and life science businesses and Beckman Coulter can consolidate its sales and marketing efforts."

Separate research and development partnerships and contract manufacturing agreements are not affected by this decision and will be continued. The two companies will also pursue a variety of collaborations, especially in the infectious disease area.

Beckman Coulter is a leading provider of instrument systems and complementary products that simplify and automate processes in life science and clinical laboratories. The company's products are used throughout the world in all phases of the battle against disease, from pioneering medical research and drug discovery to diagnostic testing that aids in patient treatment. Annual sales for the company totaled $1.8 billion in 1999, with approximately half of this amount generated outside the United States. More information on the company is available at

Bio-Rad Laboratories, Inc. ( is a multinational manufacturer and distributor of life science research products, clinical diagnostics and analytical instrumentation, based in Hercules, California. The company serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 11, 2000
Previous Article:Sun Microsystems Announces Availability of the 64-Bit UltraSPARC IIe Processor for High-End Embedded Applications.
Next Article:Visionics Announces release of Faceit--R-- Sentinel/Surveillance 2.0.

Related Articles
Beckman Coulter Officer Announces Retirement; Biomedical Industry Executive Joins Company As Successor.
Beckman Coulter Launches Immunoassay System with Networking Technology and Extensive Menu of Diagnostic Tests.
Beckman Coulter Combines Chemistry and Immunoassay Testing On Single Platform; New SYNCHRON LXi 725 System Paves Way for Safer, More Efficient...
Beckman Coulter Launches Ovarian Cancer Test, Expands Tumor Marker Menu on Immunoassay Systems.
Beckman Coulter Enters High-Volume Immunoassay Market with New, Random-Access System for Diagnostic Labs.
Beckman Coulter and AmeriNet Renew $60 Million Immunoassay Agreement.
Hycor to Develop and Supply Autoimmune Tests for Beckman Coulter; New Agreement to Accelerate Beckman Coulter's Aggressive Menu Expansion Initiative.
A study of homocysteine levels in a population of West Virginia cardiology patients.
Beckman Coulter to Market New Reagent for Metabolic Disease Screening.
Identify the Key & Niche Companies Operating in the World's Microplate Instrumentation & Supplies Industry.

Terms of use | Copyright © 2015 Farlex, Inc. | Feedback | For webmasters